Dysglycemia and liver lipid content influence the link between insulin resistance and liver mitochondrial function in obesity – Author’s reply

IF 26.8 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Journal of Hepatology Pub Date : 2024-11-08 DOI:10.1016/j.jhep.2024.11.003

Sabine Kahl, Michael Roden

{"title":"Dysglycemia and liver lipid content influence the link between insulin resistance and liver mitochondrial function in obesity – Author’s reply","authors":"Sabine Kahl, Michael Roden","doi":"10.1016/j.jhep.2024.11.003","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Financial suppport</h2>The research of the authors is supported in part by grants from the German Federal Ministry of Health (BMG), the Ministry of Culture and Science of the State North Rhine Westphalia (MKW NRW) to DDZ, and the German Federal Ministry of Education and Research (BMBF) and the MKW NRW to German Center for Diabetes Research (DZD e. V.). The research of M.R. is supported by grants from the European Community (HORIZON-HLTH-2022-STAYHLTH-02-01: Panel A) to the INTERCEPT-T2D consortium, the German Science</section></section><section><section><h2>Author contributions</h2>S.K. drafted the manuscript. S.K. and M.R. revised and approve the final version of the manuscript. M.R. is the guarantor of this work, with full access to all data and analyses related to the content of this article.</section></section><section><section><h2>ClinTrials.gov identifier</h2>NCT01477957We thank Xiyin Yang and Qiang Hu for their interest in our article [1], which investigated the association of whole-body insulin sensitivity and hepatic OXPHOS capacity in people with obesity grade 3. We would like to take the opportunity to address their comments on our study.First, the prospective BARIA-DDZ study was designed to assess metabolic changes with one focus on different features of hepatic mitochondrial function in people with obesity. For this purpose, we developed a</section></section><section><section><h2>Declaration of Competing Interest</h2>M.R. received lecture fees or served on advisory boards for AstraZeneca, Echosens, Eli Lilly, Madrigal, Merck-MSD, Novo Nordisk and Target RWE and performed investigator-initiated research with support from Boehringer Ingelheim, Novo Nordisk and Nutricia/Danone to the German Diabetes Center (DDZ). No conflicts of interest, financial or otherwise, are declared by the other authors.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"18 1","pages":""},"PeriodicalIF":26.8000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jhep.2024.11.003","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Section snippets

Financial suppport

The research of the authors is supported in part by grants from the German Federal Ministry of Health (BMG), the Ministry of Culture and Science of the State North Rhine Westphalia (MKW NRW) to DDZ, and the German Federal Ministry of Education and Research (BMBF) and the MKW NRW to German Center for Diabetes Research (DZD e. V.). The research of M.R. is supported by grants from the European Community (HORIZON-HLTH-2022-STAYHLTH-02-01: Panel A) to the INTERCEPT-T2D consortium, the German Science

Author contributions

S.K. drafted the manuscript. S.K. and M.R. revised and approve the final version of the manuscript. M.R. is the guarantor of this work, with full access to all data and analyses related to the content of this article.

ClinTrials.gov identifier

NCT01477957We thank Xiyin Yang and Qiang Hu for their interest in our article [1], which investigated the association of whole-body insulin sensitivity and hepatic OXPHOS capacity in people with obesity grade 3. We would like to take the opportunity to address their comments on our study.First, the prospective BARIA-DDZ study was designed to assess metabolic changes with one focus on different features of hepatic mitochondrial function in people with obesity. For this purpose, we developed a

Declaration of Competing Interest

M.R. received lecture fees or served on advisory boards for AstraZeneca, Echosens, Eli Lilly, Madrigal, Merck-MSD, Novo Nordisk and Target RWE and performed investigator-initiated research with support from Boehringer Ingelheim, Novo Nordisk and Nutricia/Danone to the German Diabetes Center (DDZ). No conflicts of interest, financial or otherwise, are declared by the other authors.

查看原文本刊更多论文

糖代谢异常和肝脏脂质含量影响肥胖症患者胰岛素抵抗与肝脏线粒体功能之间的联系 - 作者回复

作者的研究部分得到了德国联邦卫生部（BMG）、北莱茵威斯特法伦州文化与科学部（MKW NRW）对DDZ的资助，以及德国联邦教育与研究部（BMBF）和北莱茵威斯特法伦州文化与科学部对德国糖尿病研究中心（DZD e. V.）的资助。M.R.的研究得到了欧洲共同体（HORIZON-HLTH-2022-STAYHLTH-02-01：A组）对INTERCEPT-T2D联盟、德国科学基金会的资助。S.K. 和 M.R. 修改并批准了手稿的最终版本。M.R.是这项工作的担保人，完全有权使用与本文内容相关的所有数据和分析。ClinTrials.gov identifierNCT01477957我们感谢杨希银和胡强对我们文章[1]的关注，我们的文章研究了肥胖3级患者全身胰岛素敏感性与肝脏OXPHOS能力的关系。首先，前瞻性 BARIA-DDZ 研究旨在评估肥胖症患者的代谢变化，重点是肝线粒体功能的不同特征。为此，我们制定了一项竞争利益声明。M.R.接受了阿斯利康、Echosens、礼来、Madrigal、默克-MSD、诺和诺德和 Target RWE 的讲课费或担任顾问委员会成员，并在勃林格殷格翰、诺和诺德和 Nutricia/Danone 对德国糖尿病中心 (DDZ) 的支持下开展了由研究者发起的研究。其他作者未声明有经济或其他方面的利益冲突。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Hepatology 医学-胃肠肝病学

CiteScore

46.10

自引率

4.30%

发文量

2325

审稿时长

30 days

期刊介绍： The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.